Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Praliciguat (Primary)
Indications Diabetic nephropathies
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Akebia Therapeutics; Cyclerion Therapeutics; Ironwood Pharmaceuticals

16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
30 Oct 2019 According to a Cyclerion Therapeutics media release, the company will host a conference call and live audio webcast today o discuss the topline results from this study.
30 Oct 2019 According to a Cyclerion Therapeutics media release, full results from this study will be presented at future medical meetings.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com